
Dietary Supplementation of *Pistacia lentiscus*: Hepato-Protective Potential Against 7,12- dimethylbenz(a)anthracene Carcinogen in C57Bl/6 Mice, Alongside In Vitro Anti-Cancer Efficacy

[Omayma ABIDI](#) , [Imen Hammami](#) , [Jed Jebali](#) , [Najet Srairi-Abid](#) , [Ali Saeed Alqahtani](#) , Bernard Gressier , [Bruno Eto](#) , [Ouajdi SOUJILEM](#) *

Posted Date: 10 April 2024

doi: 10.20944/preprints202404.0726.v1

Keywords: Phytotherapy; Pistacia lentiscus; Bio-compounds; Antioxidant potential; 7,12-di-41 méthylbenz(a)anthracène; Hepato-protective



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Dietary Supplementation of *Pistacia lentiscus*: Hepato-Protective Potential Against 7,12-dimethylbenz(a)anthracene Carcinogen in C57Bl/6 Mice, Alongside In Vitro Anti-Cancer Efficacy

Omayma Abidi ^{1,2*}, Imen Hammami ³, Jed Jebali ⁴, Najet Srairi-Abid ⁴, Ali Saeed Alqahtani ⁵, Bernard Gressier ⁶, Bruno Eto ⁷ and Ouajdi Souilem ^{2,8,*}

¹ Faculty of Sciences of Tunis, University Tunis El Manar, Tunisia; Oumayma.labidi@fst.utm.tn

² Laboratory of Physiology and Pharmacology, National School of Veterinary Medicine, University of Manouba, Sidi Thabet 2020 Ariana;

³ Research Unit 17/ES/13, Faculty of Medicine of Tunis, University of Tunis El-Manar, Tunisia; hammamiimen@hotmail.fr

⁴ Laboratory of Biomolecules, Venoms and Theragnostic Applications, LR20IPT01, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; jed.jebali@pasteur.tn (J.J.); najet.abidsrairi@pasteur.tn (N.S.A.)

⁵ Department of Pharmacognosy, College of Pharmacy, King Saudi University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; alalqahtani@ksu.edu.sa

⁶ Laboratory of Pharmacology, Pharmacokinetics and Clinical Pharmacy, University of Lille, Faculty of pharmacy, 3, rue du Professeur Laguesse, B.P. 83, F-59000 Lille, France; gressier.bernard@univ-lille.fr

⁷ Laboratoires TBC, Laboratory of Pharmacology, Pharmacokinetics, and Clinical Pharmacy, Faculty of Pharmaceutical and Biological Sciences, B.P. 83 Lille, France; etobr@laboratoires-tbc.com and tobr@laboratoires-tbc.com

⁸ BiotechPole, Sidi Thabet 2020 Ariana, Tunisia;

* Correspondence: ouajdi.souilem@biotechpole.tn; Mobile: (+216) 71 537 988 - Fax: (+216) 71 537 995

Abstract: The pervasive presence of atmospheric pollution, particularly polycyclic aromatic hydrocarbons such as 7,12-dimethylbenz(a)anthracene, instigates aberrant cellular and tissue conditions, precipitating oxidative damage and inflammatory cascades conducive to the onset of cancer, notably mammary cancer. Given the hepatic metabolism of 7,12-dimethylbenz(a)anthracene, the imperative of employing natural antioxidants becomes apparent. In this study, we delve into the antioxidant and hepato-protective properties of *Pistacia lentiscus* against 7,12-dimethylbenz(a)anthracene-induced toxicity, alongside exploring its potential anticancer attributes. Our investigations unveil *Pistacia lentiscus*'s anti-proliferative efficacy against human breast cancer cell lines. Notably, 7,12-dimethylbenz(a)anthracene-intoxication escalates body weight, disrupts lipid profiles, and incites serum oxidative damage. Concurrently, hepatic and renal oxidative stress ensue, accompanied by heightened antioxidant enzyme activity in the 7,12-dimethylbenz(a)anthracene-exposed-group compared to controls ($p < 0.05$). Nonetheless, *Pistacia lentiscus* co-administration rectifies biochemical imbalances, significantly attenuates oxidative stress aberrations, and augments antioxidant enzyme responses ($p < 0.05$). Importantly, histological analysis evinces *Pistacia lentiscus*'s shielding effect against 7,12-dimethylbenz(a)anthracene induced hepatocyte injury and steatosis. Our findings underscore *Pistacia lentiscus*'s robust anti-proliferative, antioxidant, and hepato-protective capacities, mitigating metabolic disturbances, oxidative stress propagation in liver and kidney functions, and potential histological alterations, thereby impeding 7,12-dimethylbenz(a)anthracene-induced mammary cancer initiation. We posit that *Pistacia lentiscus* may serve as a prophylactic agent against breast cancer instigated by this carcinogen.

Keywords: phytotherapy; *Pistacia lentiscus*; bio-compounds; antioxidant potential; 7,12-di-41 méthylbenz(a)anthracène; hepato-protective

1. Introduction

Polycyclic aromatic hydrocarbons (PAHs) are a group of organic compounds widespread in the environment during the incomplete combustion of organic matter such as wood, coal, oil, and gas. This can occur in various settings, including certain industrial **processes, motor vehicle emissions, wildfires, tobacco smoke, grilled or charbroiled foods** (incomplete combustion of fats and juices). It can be also accumulated in soil due to deposition from the atmosphere, runoff from contaminated sites, or improper disposal of industrial waste. Its **sediments** at the bottom of rivers, lakes, and oceans, where they can persist for long periods. We can find it in aliments fish or plant [1]. Many PAHs are considered hazardous environmental pollutants due to their persistence in the environment. The exposure to high levels of PAHs has been associated with potential health risks and has been suspected carcinogens such as 7,12-dimethylbenz[α]anthracene (DMBA): a pure carcinogen substance that induce tumors in rodents. Significant exposure to DMBA can cause skin irritations, allergic reactions, respiratory disorders, and other adverse health effects [2–4].

To combat the adverse effects caused by everyday exposure to air pollution, which we often live, studies have favored the exploration of natural antioxidants to mitigate the damage from these pollutants that can lead to chronic diseases such as cancer [4].

Several researches have proven that *Pistacia lentiscus* (anacardiaceae) (PL) is characterized by important therapeutic properties [5,6]. The famous physician Avicenna mentioned this plant for its hepato-protective effects on his book *Canon of Medicine* [7]. The traditional culture of this plant was inscribed as Intangible Cultural Heritage of Humanity by UNESCO [8] for its use in folk medicine. It was cited several times in the Chilandar Medical Codex. This plant presents a promising alternative of phyto-therapeutic agents. Some bio-compounds of PL have proven liver protective effects on carbon tetrachloride (CCl₄) induced a hepatotoxicity [9]. Also, it was proven that this plant have an antioxidant effect demonstrated through the retraction of hepatic function after intoxication with sodium arsenite [10]. It has an important capacity to treat some cancers especially gastric cancers [11]. Studies have proven that PL biologic activities are strongly correlated to a high content of phenolic compounds [12,13].

As far as it could be ascertained, this is the first study investigating *PL* traditionally extracted fixed oil against DMBA-intoxication. Our study delves to investigate the in vivo antioxidant hepato-protective potential of *PL* against DMBA-intoxication on metabolic status and oxidative stress disorders in the liver and kidney of C57BL/6 female mice against the resultant steatosis and inflammation in liver, the in vitro anti-cancer effect as well as to assess the phytochemical composition of *PL* antioxidant phyto-compounds.

2. Materials and Methods

2.1. Plant Material and Fixed Oil Extraction

Pistacia lentiscus L., 1753 (Sapindales; Anacardiaceae) drupes were harvested from the region of Tabarka in December 2020, District of Jendouba, and Northeast Tunisia (Latitude: 36°57'16"N, Longitude: 8°45'29"E, altitude 108 m; annual rainfall 800-600 mm). The collected plants were identified and the certified specimen was deposited in the Herbarium of the National Research Institute of Rural Engineering Water and Forestry I.N.G.R.E.F-Tunisia under the reference VS1-PL 2009. The landscape in Tabarka region is not polluted with absence of both domestic and industrial pollution. Fixed oil (FOt) was extracted from freshly collected plants using a traditional method used in the region of Tabarka-Tunisia. Firstly, the harvested PL fruits were rinsed and stored. The black drupes (500gr) were grinded using a porcelain mortar. The mixture resulting from the grinding was put to kneading and skimming using a wooden spatula in a heated water bath. After that, the

shredded material was put in the manual press to separate the liquid phase of the waste. Then it was put to sedimentation for 24-48h and thus oil was easily recovered. The extracted FOt was stored at 8°C, until analysed.

2.2. Cell Lines

The MDA-MB-231 (ATCC® HTB-26™) and MCF-7(ATCC® HTB-22™) human breast cancer cell lines were provided by Pr. José Luis, Institute of Neuro-physiopathology, University of Aix-Marseille, France.

2.3. Animals

C57BL/6-female mice breastfed aged four weeks were purchased from the Pasteur Institute of Tunis-Tunisia. The handling of the animals was in the respect of the code of practice for the *Care and Use of Animals for Scientific Purposes* and the European Community guidelines-(86/609/EEC). The trial was approved by the Ethical Committee of the National School of Veterinary Medicine of Tunis (approval number: 14/2020/ENMV). Mice were acclimated and housed in polypropylene cages under standard controlled conditions of the animal facility of the National School of Veterinary Medicine-Tunisia: 12/12h light/dark cycle, 20±2°C temperatures, 55%±15% humidity. Food and water were *ad-libitum*.

2.4. Gas Chromatography-Mass Spectrometry Analysis (GC-MS)

Chemometric profiling was performed using a GC-MS system (Thermo Fisher Scientific, Waltham, Massachusetts, USA). The extracts were solubilised in methanol (1% v/v) and 1 µL of each sample was injected in a split mode (ratio 15:1) for 75 min, using Agilent GC7890B gas chromatography instrument coupled with an Agilent MS 240 Ion Trap (Agilent, CA, USA). The separation was accomplished in a HP-5MS capillary column (30 m×250 µm, film thickness: 0.25 µm). Helium (99.99 %) was used as carrier gas, released at a constant flow rate of 1 mL/min. The initial oven temperature started at 40°C, maintained for 2 min, then increased 5°C/min to 250°C, and held constant at this temperature for 20 min. The injector temperature was set at 280°C. The detection was made in full scan mode for 60 min. Mass spectrometry (MS) operating parameters were as follows: ion source temperature: 200°C, interface temperature: 280°C, ionizing electron energy (EI) mode: 70 eV, scan range: 50–1,000 m/z. Interpretation and identification bio-compounds were performed by comparing mass spectra with those referenced in the NIST 05 database (NIST Mass Spectral Database, PC-Version 5.0, 2005 National Institute of Standardization and Technology, Gaithersburg, MD, USA).

2.5. Experimental Design

The research plan obtained ethical clearance from the National School of Veterinary Medicine of Tunis Ethics Committee (Protocol ID Number: 14/2020/ENMV) and was in compliance with directive 2010/63/EU of animal welfare (Articles 26, 30 and 33) [14]. The experiment was carried out for 28 days in the same conditions for all animals. Mice were divided into 4 groups of 10 animals in each:

- Control-group: animals served as control and received equivalent volume of H₂O + NaCl (1ml) every day (5/7),
- DMBA-group: animals were treated with one dose per week of DMBA (20 mg/kg b.w./week) for 28 days,
- DMBA+PL-group: animals received (20 mg/kg b.w.) once a week and daily dose (5/7) of PL FOt (100 mg/kg b.w.) for 28 days,
- PL-group: animals received daily dose (5/7) of PL FOt (100 mg/kg b.w.) for 28 days,

Animals were sacrificed by decapitation according to the *American Veterinary Medicine Association Guidelines for the Euthanasia of Animals* at the end of the experiment [15]

2.6. Anthropometric Parameters

During the treatment, weight gain (g), food (g) and water (mL) intake, and blood sugar levels per mouse were taken regularly each two days. Also, blood sugar content was measured every two days through a drop of blood from the codal vein using an Accu-Chek blood meter.

2.7. Plasma Biochemical Parameters

Blood was collected in heparinized tubes for estimation of liver and kidney plasma parameters. A blood centrifugation at 3000 g for 10 min at 4°C was carried out and plasma was harvested.

Lipid profile of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and liver and Kidney function parameters of aspartate aminotransferase (AST), alanines aminotransferases (ALT), alkaline phosphatase (PAL), C-reactive protein (C-RP) (kit-ELISA), urea, creatinine (Crea) were carried out according to a standard method [16] using commercial diagnostic kits (BioSystems S.A., Costa Brava 30, 08030 Barcelona, Spain, certified according to ISO 13485 and ISO 9001).

2.8. Preparation of Homogenate and Estimation of Protein

Animals were sacrificed by decapitation then kidney and liver were quickly removed, washed in 0.9% NaCl and blotted on ash-free paper to weights. 0.4g of each tissue were placed in 4mL (50mM) phosphate buffered saline (PBS) solution (pH 7.8), homogenized and centrifuged for 15min at 9000g (4°C). Supernatants were collected and were stored at -80°C for the estimated oxidative stress biomarkers and various enzyme activities below. Total proteins in liver and kidney tissues homogenates were determined according to the biuret method [17] using serum albumin as standard. Briefly, proteins in kidney and liver supernatants constituted with copper a colorful complex measurable at 546 nm wavelength and compared to the blank. Results were expressed as mg of protein.

2.9. Oxidative Stress Biomarkers

2.9.1. Lipid Peroxidation (TBARS) Assay

The level of malondialdehyde (MDA) in liver and kidney supernatants was determined as an index of lipid peroxidation according to the double heating method (TBARS) [18]. A BHT-TCA solution (1% BHT dissolved in 20% TCA) was added to supernatant. After centrifuging at 1000g for 5 min at 4°C, the supernatants were mixed with HCl (0.5), TBA-Tris (TBA (120 mM) dissolved in Tris (26 mM)), then heated for 10 min at 80°C. After that the mixture was put directly in ice for cooling to stop the activity of the resulting chromophore. The MDA levels were determined by using an extinction coefficient for the MDA-TBA complex of $1.56 \text{ M}^{-1} \text{ cm}^{-1}$ and expressed as nmol/mg protein.

2.9.2. Sulfhydryl Groups (-SH) Determination

Sulfhydryl groups concentration (-SH) was performed according to the method Ellman et al. (1959). Briefly, liver and kidney homogenates were each mixed with 100mL of EDTA (20mM; pH 8.2). Mixture was vortexed and absorbance was measured at 412 nm (A1). Then, 100mL of DTNB (10mM) was added to the mixture incubated for 15min and the optic density was measured at 412nm (A2). Results were calculated as $(A2-A1-B) * 1.57 \text{ mM}$ where B was the blank. The concentration of the sulfhydryl group was expressed as nmol /mg of protein [19].

2.9.3. Hydrogen Peroxide (H₂O₂) Determination

Hydrogen peroxide was measured according to a standard colorimetric technique of Kakinuma et al. (1979), using available kit (BioSystems S.A., Costa Brava 30, 08030 Barcelona, Spain, certified according to ISO 13485 and ISO 9001). Briefly, H₂O₂ forms a red colored quinoa-eradicat after

interaction with 4-amino-antipyrine and phenol. Absorbance was read at 505 nm and results were deduced from a standard calibration curve and expressed as nmol/mg protein [20].

2.10. Enzymes Antioxidant Capacity

The determination of enzymatic antioxidant activities was accomplished by detection of the glutathione peroxidase activity (GPx) performed according to the method of Rotruck *et al.*, (1980). Briefly, 0.2 mL of liver and kidney tissues homogenates were added to 0.2 mL of phosphate buffer (0.1 M, pH 7.4), 0.2 mL of GSH (4 mM) and 0.4 mL of H₂O₂ (5 mM). Then, the reaction mixture was incubated for 1 min at 37°C. Centrifugation was carried out for 5 min at 1500 g, after adding 0.5 mL of TCA (5%) to block the reaction. The supernatant (0.2 mL) was collected and mixed with 0.5 mL of DTNB (10 mM) and phosphate buffer (0.1 M, pH 7.4) [21]. The glutathione peroxidase activity was measured at 412 nm wavelength and compared to the blank. Results were expressed as UI/mg of protein. The catalase activity CAT was also measured according to a standard method [22] and expressed as $\mu\text{mol H}_2\text{O}_2/\text{min}/\text{mg}$ of protein. The superoxide dismutase enzyme SOD activity was measured according to a standard method [22] and expressed as Unity U SOD/mg of protein.

2.11. Histopathological Analysis

Directly after euthanasia, small pieces of liver and kidney were removed, washed with NaCl (0.9%) and were preserved in a buffered neutral formalin solution (10%). After dehydration with ethanol then xylene, samples were finished in paraffin to be cut into 0.2 μm thick sections. Putting on the slides, the sections were deparaffinized, hydrated (with decreasing concentrations of ethanol) to facilitate their staining with hematoxylin and eosin.

2.12. In Vitro Anticancer Effect

MDA-MB-231 and MCF7 cell lines were initially seeded in 96-well culture plates at a concentration of 10⁴ cells/well. Following this seeding, the cells were subjected to incubation either alone or in escalating concentrations of PL F0t. After incubation periods of 24 hours or 72 hours, cellular viability and proliferation were evaluated through the utilization of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium reduction colorimetric MTT assay, as described by Mosmann in 1983 [23]. Subsequently, cells were fixed with 3.7% formaldehyde, stained with 0.1% crystal violet, and lysed with SDS. Absorbance readings were taken at 560 nm wavelengths using a Multiskan microplate reader (Lab systems, GmbH). The untreated cells (medium) served as the positive control, and the results were presented as percentages of viable cells compared to the non-treated cells used as controls.

2.13. Statistical Analysis

The data was analysed using GraphPad Prism 8.4.2 Software (La Jolla, CA, USA). Data were determined by one-way analysis of variance (ANOVA), followed by Tukey post hoc test, and was expressed as the mean \pm standard error (SEM). All statistical tests were three-tailed and a *P* value of 0.05 or less was considered significant.

3. Results

3.1. Gas Chromatography-Mass Spectrometry Analysis (GC-MS)

The chromatographic crude profile had depicted 6 peaks of fatty in 100% of PL F0t. The key chemotypes were: 1H-Indole-3-acetic acid, methyl ester (53.8%) and Benzeneacetic acid (13.66%). Other bio-compounds were: Methy(1Z,14Z,17Z)-eicosatrienoate (11.96%), Hexadecanoic acid (9.86%), 13-octadecenoic acid (5.548%) and Bicyclo(2.2.1)heptan-2-one (5.218%). Compounds were ranked according to their elution on Rtx-5MS capillary column in Table. 2. (Supplementary Information Figure S1).

Table 1. Gas chromatography-mass spectrometry' fatty acid identification of *Pistacia lentiscus* traditionally extracted fixed oil.


Peaks N°	Retention time (min)	Library identified compound name/ID	Area (%)	Chemical class	Molecular formula
1	18.018	Bicyclo(2.2.1)heptan-2-one, 1	05.2	Cyclic monoterpene	C ₇ H ₁₀ O
2	19.078	Benzeneacetic acid	13.7	Monocarboxylic acid	C ₈ H ₈ O ₂
3	34.896	1H-Indole-3-acetic acid, methyl ester	53.8	Methyl ester	C ₁₁ H ₁₁ NO ₂
4	36.922	Hexadecanoic acid, acidethyl	09.9	Fatty acid ester	C ₁₆ H ₃₂ O ₂
5	40.103	Methy (11Z,14Z,17Z)-eicosatrienoate	11.9	Acid methyl ester	C ₂₁ H ₃₆ O ₂
6	40.211	13-octadecenoic acid, methyl	05.5	Monocarboxylic acid	C ₂₈ H ₅₀ O ₆
		Monoterpene	05.2		
		Fatty acid	19.2		
		Ester	75.6		
		Total identified	100%		

Compounds are listed in order of their elution on Rtx-5MS capillary column. Interpretation and identification were based on a comparison of the compounds mass spectral data and Kovats retention indices (RI) with those of NIST Mass Spectral 05 Library database (2011), Wiley Registry of Mass Spectral Data 8th edition and literature. The data presented are the mean values of three replicates.

3.2. Anthropometric Parameters

Weight gain, food and water intake and glycemia were carried out during our study, from the start of the experiment until euthanasia and were presented in Figure 1.

The DMBA group had a significant body weight loss (16%) during the 28 days of the treatment compared to the control (25 ± 0.92 g) and co-treated groups (23 ± 0.5 g) (Figure 1A). Also, the food intake had decreased (3 ± 0.2 g) compared to the control group (5 ± 0.3 g) (Figure 1B). However, the water intake had increased (6 ± 0.32 mL) compared to control (4 ± 0.8 mL) and co-treated groups (5 ± 0.3 mL) (Figure 1C–F). The blood sugar levels revealed an increase in glycemia for the DMBA group (3.9 ± 0.09 g/L) compared to the control and PL groups (stable in 3.5 ± 0.04 g/L). The blood sugar level in the co-treated group (3.75 ± 0.06 g/L) was moderated compared to the DMBA group (Figure 1G).






Figure 1. Anthropometric parameters of body weight gain, water intake, food intake and blood sugar levels of C57/B6 female mice during the DMBA-treatment period and the protective effect of *Pistacia lentiscus*. Animals were pretreated 28 days per oral (p.o), one dose per week of DMBA (20 mg/kg, b.w.) alone for the DMBA group and with addition of daily dose (5/7) of fixed oil of PL (100 mg/kg, b.w. p.o) in the DMBA + PL group. The PL was treated with daily dose (5/7) of fixed oil of PL (100 mg/kg, b.w. p.o). While the control group was treated with (0.9%) NaCl every day (5/7). Values are given as median and (minimum value- maximum value), $p < 0.05$ (ANOVA test).

All these anthropometric parameters were corrected in the co-treated DMBA+PL group. The PL group had no significant change compared to the control group ($p < 0.05$). Values are given as median for (n=10) per group.

3.3. Plasma Biochemical Parameters

Our results have proven that PL had a corrector effect of the biochemical plasmatic parameters on DMBA perturbations (Table 2.).

This study has proven an increase in the liver plasmatic parameters in the DMBA group (AST: 230 UI/I; ALT: 130 UI/I; PAL: 249 UI/I) compared to the control group (AST: 196 UI/I; ALT: 98 UI/I; PAL: 166 UI/I) (Table 2.) ($p < 0.05$). The kidney plasmatic parameters were higher than normal in the DMBA group (urea: 0.9 g/L; creatinine: 6.2 mg/L) compared to the control group (urea: 0.6 g/L; creatinine: 4.9 mg/L).

In the some DMBA group, metabolic parameters of lipid profile (TC: 1.5 g/L; TG: 2.2 g/L; HDL: 1.5 g/L; LDL: 1.2 g/L) were higher than normal compared to the control group (TC: 1 g/L; TG: 1.9 g/L; HDL: 1.1 g/L; LDL: 0.9 g/L). However, liver and kidney function (AST: 213 UI/I; ALT: 158 UI/I; PAL: 223 UI/I; urea: 0.7 g/L; creatinine: 9.5 mg/L) and metabolic parameter of lipid profile (TC: 1.2 g/L; TG: 2g/L; HDL: 1.2 g/L; LDL: 1 g/L) of the co-treated group (DMBA+PL) are significantly decreased compared to DMBA group ($p < 0.05$).

The PL group had no significant change (AST: 192 UI/I; ALT: 110 UI/I; PAL: 162 UI/I; urea: 0.48 g/L; creatinine: 4.1 mg/L). Slide diminution was marked in the lipid profile (TC: 0.9 g/L; TG: 1.8 g/L; HDL: 1 g/L; LDL: 0.8 g/L) compared to the control group.

Table 2. Biochemical parameters of lipid profile, liver and kidney function and blood glucose content.

	Lipid profile				Liver function				kidney function	
	TC (g/L)	TG (g/L)	HDL (g/L)	LDL (g/L)	ALT (UI/I)	AST (UI/I)	PAL (UI/I)	C-RP (µg/dL)	Crea (mg/L)	Urea (g/L)
Group control	1 ± 0.2	1.9 ± 0.1	1.1 ± 0.2	0.9 ± 0.1	98 ± 52	196 ± 72	212 ± 38	0.9 ± 0.6	4.9 ± 0.9	0.6 ± 0.1
Group P.L	0.9 ± 0.03	1.8 ± 0.5	1 ± 0.03	0.8 ± 0.05	96 ± 62	186 ± 82	204 ± 50	0.82 ± 0.7	4.9 ± 0.5	0.6 ± 0.05
Group DMBA	1.5 ± 0.2 ^a	2.2 ± 0.9 ^a	1.5 ± 0.2 ^a	1.2 ± 0.09 ^a	130 ± 88 ^a	230 ± 51 ^a	249 ± 65 ^a	1.5 ± 0.7 ^a	6.2 ± 0.5 ^a	0.9 ± 0.09 ^a
Group DMBA+ P.L	1.2 ± 0.1 ^b	2 ± 0.8 ^b	1.2 ± 0.1 ^b	1 ± 0.1 ^b	158 ± 73 ^b	213 ± 62 ^b	223 ± 51 ^b	1.1 ± 0.3 ^b	5.9 ± 0.3 ^b	0.7 ± 0.1 ^b

Values were expressed as mean ± SEM for different groups (n = 10), ($p < 0.05$). DMBA:

Dimethylbenz[a]anthracene; TC: Total cholesterol; TG: Triglyceride; HDL: high density level; LDL: low density level; AST: aspartate aminotransferase; ALT: alanines aminotransferases; PAL: alcalin phosphatase; C-RP: C-reactive protein; Animals were pretreated 28 days with one dose per week of DMBA (20 mg kg, b.w.) alone for the DMBA group and with addition of daily dose (5/7) of fixed oil of PL (100 mg kg, b.w.) in the DMBA + PL group. The PL group was treated with daily dose (5/7) of fixed oil of PL (100 mg kg, b.w.). While the control group was treated with (0.9%) NaCl every day (5/7). Values are given as median and (minimum value- maximum value), ** $p < 0.05$: compared to the control group, (ANOVA test) and * $p < 0.05$: Compare to DMBA group (ANOVA test).

3.4. Oxidative Stress Biomarkers

3.4.1. In Liver Tissues

The levels of oxidative stress parameters were evaluated and proven that DMBA pretreatment increased the levels of lipid peroxidation (MDA) in liver tissues (7.127 nmol/mg Pr) (Figure 2A), increase oxygen peroxide (H_2O_2) (18.48 nmol/mg Pr and 15.4 nmol/mg Pr, respectively) (Figure 2C) and also thiol groups (-SH) content (9.2 nmol/mg Pr) (Figure 2B) compared to the control group, where the levels of oxidative stress parameters in liver tissues were normal: 3.553 nmol/mg Pr, 9.75 nmol/mg Pr and 5.3 nmol/mg Pr, respectively (Figure 2A–C) ($p < 0.05$). Although, the co-treated DMBA+PL group proved a corrective effect of FOt on oxidative damage induced by the DMBA co-treatment in the measurement of MDA (6.01 nmol/mg Pr), -SH (7.3 nmol/mg Pr) and H_2O_2 (11.99 nmol/mg Pr) compared to DMBA groups ($p < 0.05$).

3.4.2. In Kidney Tissues

The levels of oxidative stress biomarkers were also evaluated in kidney tissues. DMBA pretreatment increase the levels of MDA (5.28 nmol/mg Pr) tissues (Figure 2A), increases H_2O_2 (15.4 nmol/mg Pr) (Figure 2C) and -SH (5.9 nmol/mg Pr) (Figure 2B) compared to the control group where levels of oxidative stress parameters of MDA, H_2O_2 and -SH were higher (4.22 nmol/mg Pr, 3.3 nmol/mg Pr and 5.5 nmol/mg Pr, respectively). The co-treated DMBA+PL group has decreased the levels of these parameters compared to the DMBA group ($p < 0.05$). Oxidative stress biomarkers were higher in liver tissues than kidney tissues. However, this parameter was stable in the PL group in both tissues.

3.5. Enzymes Antioxidant Capacity

The enzymatic antioxidant activities were accomplished in both liver and kidney tissues in all groups (Figure 2).

3.5.1. In Liver Tissues

The DMBA treatment in C57BL/6 female mice increases the activities of the antioxidant enzymes in the liver such as: SOD (3.85 UI/mg Pr) (Figure 2D), CAT (36.35 $\mu\text{mol H}_2\text{O}_2/\text{min}/\text{mg Pr}$) (Figure 2E) and GPx (6.22UI/mg Pr) (Figure 2F) compared to the control group (0.96 UI/mg Pr, 25.31 $\mu\text{mol H}_2\text{O}_2/\text{min}/\text{mg Pr}$ and 5.05 UI/mg Pr, respectively) ($p<0.05$). However, the co-treated mice with DMBA+PL have a corrector effect in antioxidant enzymes biomarkers of liver tissues.

3.5.2. In Kidney Tissues

Antioxidant enzyme activities have also increased in the DMBA group: SOD (1.692 UI/mg Pr) (Figure 2D), CAT (16.973 $\mu\text{mol H}_2\text{O}_2/\text{min}/\text{mg Pr}$) (Figure 2E) and GPx (3.88UI/mg Pr) (Figure 2F) compared to the control group (0.457 UI/mg Pr, 9.39 $\mu\text{mol H}_2\text{O}_2/\text{min}/\text{mg Pr}$ and 1.753 UI/mg Pr, respectively) ($p<0.05$). The co-treatment with PL FOt corrected the levels of these parameters. The PL group has normal levels of antioxidant enzyme activities in both kidney and liver tissues compared to the control group ($p<0.05$).




Figure 2. The protective effect of *Pistacia lentiscus* against the 7,12-dimethylbenz(a)anthracene, inducing oxidative stress and antioxidant enzyme disorders in liver and kidney tissues of C57BL/6-female mice. a, b, c: oxidative stress disorders in MDA, -SH and H_2O_2 parameters, respectively. d, e, f: antioxidant activity of SOD, CAT and GPx, respectively. Animals were pretreated 28 days per oral (p.o), one dose per week of DMBA (20 mg kg, b.w.) alone for the DMBA group and with addition of daily dose (5/7) of fixed oil of PL (100 mg kg, b.w. p.o) in the DMBA + PL group. The PL was treated with daily dose (5/7) of fixed oil of PL (100 mg kg, b.w. p.o). Values are given as median and (minimum value- maximum value), ** $p<0.05$: compared to the control group, (ANOVA test) and * $p<0.05$: Compare to DMBA using non-parametric Kruskal-Wallis's test.

3.6. Histopathology Section

The observation of liver tissues of different groups used in this study (control, PL, DMBA and DMBA+PL) showed several structural modifications especially on DMBA group (Figure 3).

In this group, liver lobules appear disorganized indicating hepatocytes injury. The observation showed several areas of overload of fat in hepatocytes cytoplasm: the steatosis aspect (red arrows) with different areas of dilated sinusoids containing many inflammatory and red cells near to portal space (PS). These disturbances were absent in the control, PL and DMBA+PL groups (Figure S2).




Figure 3. *Pistacia lentiscus* protective effect against the 7,12-dimethylbenz(a)anthracene induced histo-pathologic alteration in liver and kidney tissues of C57/B6 female mice. A: The liver (H&E) Microscopic observation (X10 on the left), B: The liver Microscopic observation (X40 on the between), (n= 10/group) Animals were pretreated 28 days per oral (p.o), one dose per week of DMBA (20 mg kg, b.w.) alone for the DMBA group and with addition of daily dose (5/7) of fixed oil of PL (100 mg kg, b.w. p.o) in the DMBA + PL group. The PL was treated with daily dose (5/7) of fixed oil of PL (100 mg kg, b.w. p.o). H: hepatocytes injury, *: dilated sinusoids, PS: the portal space. Black arrows: accumulation of inflammatory and red cells.

Weight gain, food and water intake and glycemia were carried out during our study, from the

The observation of kidney parenchyma of different groups (control, PL, DMBA and DMBA+PL) used in this study showed normal architecture of kidney sections (Figure 4). The cortex of this organ is distinguished by characteristic renal corpuscles, each of which consists of an outer envelope of simple squamous epithelium (Bowman capsule, BC) surrounding a fluid-filled space (Bowman space, S) within which is suspended a glomerulus (G). The proximal tubule (P) with cuboidal epithelium is immediately adjacent to Bowman space (S). The glomerulus contains endothelial cells, podocytes,

and mesangial cells. The major section of the cortex consists of convoluted tubules. Cells comprising proximal tubules (P) stain more intensely eosinophilic than those comprising distal tubules (D). The lumens of distal tubules (D) commonly appear more open and clearer than those of proximal tubules (P) (Figure 4.).




Figure 4. Protective effect of Pistacia lentiscus traditionally extracted fixed oil on DMBA induced histo-pathologic alteration in kidney tissues of C57/B6 female mice. Microscopic observation (X40) in the kidney (H&E) of A: the control group, B: PL group treated with fixed oil of PL 100 mg/kg bw daily dose (5/7), C: DMBA group treated with 20 mg/kg b.w dose per week for 28 days and D: DMBA+ PL group treated with fixed oil of PL at 100 mg/kg bw daily dose (5/7) dose and DMBA at 20 mg/kg bw dose per week for 28 days. BC: Bowman capsule, S: Bowman space, G: a glomerulus, P: The proximal tubule, S: Bowman space, D: distal tubules.

3.7. *In Vitro* Anticancer Effect

PL FOt was evaluated against the proliferation on human breast cancer adenocarcinoma. The reduction effect of PL in cell viability has been mentioned in a dose-dependent decrease in MDA-MB-231 and MCF-7 cells viability from the first 24h (Figure 5A) and after 72hrs of treatment (Figure 5B).

PL extract has an anti-proliferative effect on MDA-MB-231 ($IC_{50} = 8$ mg/ml) and MCF-7 ($IC_{50} = 3.2$ mg/ml) cells (Figure 5.).




Figure 5. Effect of *Pistacia lentiscus* FOT extracted fixed oil on MCF-7 and MDA-MB cell viability (A) and cell proliferation (B).

4. Discussion

In the present study we investigated the toxicity of DMBA carcinogen induced oxidative damage in liver tissues on C57BL/6 female mice as well as the hepato-protective potential of *PL* FOT bio-compounds on the induced oxidative stress.

The *PL* composition underwent a chromatographic identification. We found that FOT GC-MS analysis has depicted new chemotypes, mainly: 1H-Indole-3-acetic acid, Benzeneacetic acid, methyl ester, Hexadecanoic acid, 13-octadecenoic acid and Bicyclo (2.2.1) heptan-2-one,1. These bio-compounds belong to monoterpenes, fatty acid and ester classes. Previous phytochemical studies carried out on *PL*, have proven that FO was rich in alpha-pinene, beta-myrtene, beta-pinene, limonene and beta-karyophyllene. FOT is a combination of terpenes where α -pinene (67%) can be the significant compounds. Some combination with myrcene induced can give a potent anticancer effect [11]. It is also characterized by the presence of flavanol glycosides (flavonoids) (Table 2 and Figure A1) such as: quercetin, myricetin, luteolin, isoflavone genistein, gallic acid and quinic acid [24].

The main objective of this research was to evaluate the hepato-protective effect and antioxidant potential of *PL* vs DMBA-oxidative damage on C57BL/6 female mice. Overall, the DMBA treatment induced an increase in body weight, water intake, blood sugar levels and a decrease in food intake compared to control and co-treated groups ($p < 0.05$). *PL* extract has a corrective effect in anthropometric parameters of weight, water intake, food intake and blood sugar levels compared to the DMBA group (Figure 1.) ($p < 0.05$).

Our study has proven that DMBA induced an increase in lipid profile, liver function parameters and kidney function parameters (Table. 2.) compared to the control group and *PL* group ($p < 0.05$). While the same parameters have decreased in the co-treated group compared to DMBA group (Table. 2.) ($p < 0.05$). Some metabolic disorders can be caused by a high-fat diet that can induce oxidative stress in C57BL/6 mice, leading to TG accumulation and hepatic steatosis [25]. It was proven that oxidative stress induced by an intra-peritoneal hepatotoxic injection in C57BL/6 mice significantly increased the serum hepatic transaminase (ALT, myeloperoxidase), cytokines (TNF- α , IL-6, and IL-17), and lipid peroxidation [26]. On the other hand, study have proven that different concentrations of *PL* FO (0.1%-5%) reduced the cell viability of human fat cells [27].

Our result proved that DMBA induced disturbance in oxidative stress biomarkers (MDA, H₂O₂ and -SH) in liver and kidney tissues (Figure 2a-c) (Figure A2). Our results agree with other research proving that DMBA can cause an increase in ROS production, leading to lipid peroxidation and damage to liver cells. It was proven that DMBA significantly modulates cutaneous lipid peroxidation and induced an exhaustion of total antioxidant capacity that consequently inducing skin cancer [28].

DMBA may also interfere with the normal antioxidant defense mechanisms and enzymes antioxidant activities (SOD, CAT, GPx) in liver and kidney cells (Figure 2d–f). Antioxidants are molecules that can neutralize ROS and prevent oxidative damage. However, exposure to DMBA may reduce the levels of antioxidants in liver cells, making them more susceptible to oxidative stress and damage. Moreover, oxidative stress can lead to cellular damage and it is implicated in the development of various diseases, including liver and kidney disorders.

Antioxidants are bio-compounds that help protect cells from oxidative stress and damage caused by ROS, which are highly reactive molecules that can harm cellular components like DNA, proteins, and lipids [28]. In this context, the most important result drawn from the present study is the corrector effect of *PL* to prevent oxidative damages in liver. FOT decrease the lipid profile of *PL* group compared to the control and in the cotreated group compared to DMBA group ($p < 0.05$) (Table 2.). Also, it has a potent antioxidant therapeutic effect that increases the antioxidant enzymes and reduces stress biomarkers in liver and kidney tissues. Our results are in agreement with results showing the antioxidant potential of *PL* extracts [9]. There is some promising evidence to suggest that *PL* may have hepato-protective effects [7]. Moreover, it has been proven that this plant has a corrective effect on the retraction of hepatic function after sodium arsenite intoxication [9]. *PL* has relatively mitigated oxidative damage and can exhibit an increase in hepatic antioxidant enzymes [10].

In the present study, our histology data has proven that DMBA treatment induced alteration in hepatocytes cells while no significant funding has been proven in the kidney in the short-term treatment (28 days). Several research have proven that exposure to DMBA led to the activation of an enzyme called sterol regulatory element-binding protein-1c (SREBP-1c), which is known to promote lipid synthesis in liver cells. The activation of SREBP-1c resulted in an increase in the expression of genes involved in fatty acid synthesis and lipid accumulation, leading to the development of steatosis. Some medicinal plant can be a potential hepato-protective agent. *Artemisia annua* leaf extract attenuates hepatic steatosis and inflammation in high-fat diet-fed mice [9]. *PL* induces tumor-suppressing effects against experimental colon cancer [11,29]. Thus, these hepato-protective effects were attributed to the presence of bioactive compounds, such as polyphenols and flavonoids, which are known to possess antioxidant properties [12].

Our findings finding has proven an anti-proliferative potential of *PL* FOT unveiled in a dose dependent manner (Figure 5). Our results agree with studies reporting that *PL* extracts blocks the differentiation of cancerous of 13 types of human tumour/leukaemia cells, CRC HCT116 cell lines and gastric cancer [11,29]. These naturally occurring phyto-compounds contribute to various biological activities and health benefits. Phytochemicals with antioxidant effects play a crucial role in maintaining cellular health and reducing the risk of chronic diseases, including cardiovascular diseases, cancer, and neurodegenerative disorders.

It has been proven that oxidative stress results in abnormal circumstances at the cellular and tissues levels, inducing the development and progression of liver cancers [10]. In fact, oxidative stress is closely linked to the accumulation of fat in liver cells. The excessive accumulation of fat (triglycerides) in hepatocytes can lead to several conditions such as lipid peroxidation, mitochondrial dysfunction, inflammation, DNA damage and antioxidant defenses perturbation, fibrosis [9] and even liver cancer in rare cases [10]. In addition, the liver normally has a finely tuned system of pro-inflammatory and anti-inflammatory signals that maintain tissue homeostasis. However, exposure to oxidative stress may disrupt this balance and lead to an excessive or deregulated inflammatory response (Figure 3). It can stimulate the production of cytokines and chemokines by these immune cells, leading to the recruitment of more immune cells to the liver and the initiation of an inflammatory response that can cause damage to liver cells and contribute to the development of steatosis [26]. Moreover, fatty liver disease can cause changes in the way liver cells metabolize certain compounds, which can also contribute to the development of liver cancer [28]. Overall, it may also have other coexisting conditions such as diabetes, obesity, and metabolic syndrome, which are also known to increase the risk of fatty liver disease and liver cancer.

One possible explanation for the link between fatty liver disease and cancer is that chronic inflammation and oxidative stress caused by the accumulation of fat in liver cells can damage DNA and other cellular components, leading to mutations that promote the development of cancer [9].

There is evidence to suggest that *PL* extract may have a protective effect against steatosis. Supplementation diet with *PL* reduced the accumulation of fat in the liver [30] which improve liver function. One possible mechanism is through its antioxidant properties: *PL* is rich in antioxidants, such as polyphenols and flavonoids [6], which can scavenge free radicals and reduce oxidative stress in liver cells [10,13,26]. *PL* bio-compounds may have antioxidant and anti-inflammatory properties to inhibit the production of pro-inflammatory cytokines and chemokines, which can reduce inflammation in the liver.

5. Conclusions

In the present study, the crude chemical profiles of *PL* FOt revealed the presence of six various fatty acids bio-compounds. Importantly, DMBA-oxidative stress induced steatosis and disturbances in liver parameters of female C57BL/6 mice. Also, body weight increases, metabolic disorders in lipid parameters and glycaemia have been detected. Moreover, DMBA-intoxication disturbed liver and kidney functions in plasma parameters, increased oxidative stress in liver and kidney tissues then consequently increased the antioxidant enzymes response. More importantly, *PL* proved a protective effect in liver that mitigate the threat of potential metabolic disorders, the spread of oxidative stress in liver and kidney functions and the potential histologic alteration specially in liver. This therapeutic effect is strongly related to the high antioxidant bio-compounds and antioxidant enzymes. Our study has proven that *PL* has an important antioxidant and hepato-protective potential. *PL* consumption might be promising protective agents against PHAs-environmental pollution.

6. Patents

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org, Figure S1: GC-MS analysis of *Pistacia lentiscus*; Figure S2: Real pictures of livers in different treated groups.

Author Contributions: Conceptualization, O.S., O.A.; methodology, I.H., J.J., O.A.; writing original draft preparation, software, data curation, formal analysis, O.A.; validation, investigation, visualization, A.-S.A., N.S.-A., B.E.; review and editing, supervision, project administration, O.S. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by the Researchers Supporting Project number (RSP2023R132), King Saud University, Riyadh, Saudi Arabia

Institutional Review Board Statement: The study was approved by the Ethics Committee THE NATIONALE SCHOOL OF VETERINARY MEDECINE of SIDI THABET of CEEA-ENMV (protocol code 14/2020/ENMV and date of approval: 30.03.2020).

Data Availability Statement: Informed consent was obtained from all subjects involved in the study.

Acknowledgments: We thank all editors and reviewers. We are grateful to Ministry of Higher Education and Scientific Research of Tunisia and its institutes: University of Tunis el Manar, Pastor Institut of Tunisia, Faculty of Medicine of Tunisia and the National school of Veterinary Medicine. Also, we are grateful to Laboratoires TBC, Faculty of pharmacy, University of Lille France. The authors are thankful to the King Saud University, Riyadh, Saudi Arabia.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Blumer, M. and W.W. Youngblood, *Polycyclic aromatic hydrocarbons in soils and recent sediments*. Science, 1975. **188**(4183): p. 53-55.
2. Ananda, H., et al., A trisubstituted pyrazole derivative reduces DMBA-induced mammary tumor growth in rats by inhibiting estrogen receptor- α expression. *Molecular and Cellular Biochemistry*, 2018. **449**(1): p. 137-144.

3. Sofi, M.S., et al., Chemopreventive and anti-breast cancer activity of compounds isolated from leaves of *Abrus precatorius* L. *3 Biotech*, 2018. **8**(8): p. 1-14.
4. Omayma, A., Zaineb, Abdelkafi-Koubaa., Ilhem Bettaieb-Dridi, Lamjed Toumi, Lamjed Marzouki, and Ouajdi Souilem, *Pistacia lentiscus* L. revealed potential anti-inflammatory, antioxidant and antiproliferative enhancement in vitro breast cancer cells and in vivo DMBA-C57BL/6 mammary cancer. *PLOS ONE*, 2024.
5. Bagheri, S., et al., Effects of *Pistacia atlantica* on oxidative stress markers and antioxidant enzymes expression in diabetic rats. *Journal of the American College of Nutrition*, 2019. **38**(3): p. 267-274.
6. Omayma, A., Zaineb, Abdelkafi-Koubaa., Nadia Fares-Zagrouba., Salem Elkahoui., Lamjed Toumi., Lamjed Marzouki., and Ouajdi Souilem, *HYTOCHEMICAL ANALYSIS AND BIOLOGICAL ACTIVITIES OF TWO OIL-BEARING EXTRACTS FROM FRESH PISTACIA LENTISCUS*. *Bull. Chem. Soc. Ethiop.*, 2023. **37**(6): p. 1487-1501.
7. Shamsi-Baghbanan, H., et al. *Hepatoprotective herbs, avicenna viewpoint*. *Iranian Red Crescent Medical Journal*, 2014. **16**(1):e12313, DOI: 10.5812/ircmj.12313.
8. Nikolakopoulou, V., et al., Conveying Intangible Cultural Heritage in Museums with Interactive Storytelling and Projection Mapping: The Case of the Mastic Villages. *Heritage*, 2022. **5**(2): p. 1024-1049.
9. Kim, K.E., et al., *Artemisia annua* leaf extract attenuates hepatic steatosis and inflammation in high-fat diet-fed mice. *Journal of medicinal food*, 2016. **19**(3): p. 290-299.
10. Klibet, F., et al., Oxidative stress-related liver dysfunction by sodium arsenite: Alleviation by *Pistacia lentiscus* oil. *Pharm. Biol.*, 2016. **54**(2): p. 354-363.
11. Spyridopoulou, K., et al., Dietary mastic oil extracted from *Pistacia lentiscus* var. chia suppresses tumor growth in experimental colon cancer models. *Scientific reports*, 2017. **7**(1): p. 3782.
12. Belyagoubi-Benhammou, N., et al., Fatty acid composition and antioxidant activity of *Pistacia lentiscus* L. fruit fatty oil from Algeria. *J. Food Meas. Charact.*, 2018. **12**: p. 1408-1412.
13. Abidi, O., et al., Phytochemical analysis and biological activities of two oil-bearing extracts from fresh *Pistacia lentiscus*. *Bulletin of the Chemical Society of Ethiopia*, 2023. **37**(6): p. 1487-1501.
14. Hawkins, P., et al., A guide to defining and implementing protocols for the welfare assessment of laboratory animals: eleventh report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. *Laboratory Animals*, 2011. **45**(1): p. 1-13.
15. AVMA American Veterinary Medical Association guidelines for the euthanasia of animals: 2020 edition. 2020. **2020.0.1**, 1-121.
16. Reitman, S. and S. Frankel, A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *American journal of clinical pathology*, 1957. **28**(1): p. 56-63.
17. Ohnishi, S.T. and J.K. Barr, A simplified method of quantitating protein using the biuret and phenol reagents. *Analytical biochemistry*, 1978. **86**(1): p. 193-200.
18. Draper, H.H. and M. Hadley, *Malondialdehyde determination as index of lipid Peroxidation*. *Methods Enzymol.*, 1990. **186**: p. 421-431.
19. Ellman, G.L., *Tissue sulfhydryl groups*. *Arch. Biochem. Biophys.*, 1959. **82**(1): p. 70-77.
20. Kakinuma, K., et al., A Determination of H₂O₂ Release by the Treatment of Human: Blood Polymorphonuclear Leukocytes with Myristate. *The Journal of Biochemistry*, 1979. **86**(1): p. 87-95.
21. Rotruck, J., et al., Selenium: biochemical role as a component of glutathione peroxidase. *Nutrition Reviews*, 1980. **38**(8): p. 280-283.
22. Kakkar, P., B. Das, and P. Viswanathan, *A modified spectrophotometric assay of superoxide dismutase*. *Indian Journal of Biochemistry & Biophysics*, 1984. **21**: p. 130-132.
23. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods*. 1983. **65**(1-2): p. 55-63.
24. Vaya, J. and S. Mahmood, Flavonoid content in leaf extracts of the fig (*Ficus carica* L.), carob (*Ceratonia siliqua* L.) and pistachio (*Pistacia lentiscus* L.). *Biofactors*, 2006. **28**(3-4): p. 169-175.
25. Yuan, G., et al., Supplementation with Docosahexaenoic Acid and Vitamin E Improves Hepatic Triglyceride Accumulation Induced by High-Fat Diet in Mice. *European Journal of Lipid Science and Technology*, 2021. **123**(1): p. 2000224.
26. Liao, C.-C., et al., Baicalin attenuates IL-17-mediated acetaminophen-induced liver injury in a mouse model. *PLoS One*, 2016. **11**(11): p. e0166856.
27. Ostovan, M., et al., The short-term effects of *Pistacia lentiscus* oil and sesame oil on liver and kidney pathology of rats and human cancer cell lines. *Galen Medical Journal*, 2020. **9**: p. e2001.
28. Sahoo, H.B., D.D. Santani, and R. Sagar, Chemopreventive potential of *Apium leptophyllum* (Pers.) against DMBA induced skin carcinogenesis model by modulatory influence on biochemical and antioxidant biomarkers in Swiss mice. *Indian Journal of Pharmacology*, 2014. **46**(5): p. 531.
29. Balan, K., et al., Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from *Pistacia lentiscus* L. var. chia. *Phytomedicine*, 2007. **14**(4): p. 263-272.

30. Pachi, V.K., et al., Traditional uses, phytochemistry and pharmacology of Chios mastic gum (*Pistacia lentiscus* var. *Chia*, Anacardiaceae): A review. *Journal of Ethnopharmacol*, 2020. **254**: p. 112485.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.